Novel factors modulating human ß-cell proliferation.

ß-Cell dysfunction in type 1 and type 2 diabetes is accompanied by a progressive loss of ß-cells, and an understanding of the cellular mechanism(s) that regulate ß-cell mass will enable approaches to enhance hormone secretion. It is becoming increasingly recognized that enhancement of human ß-cell proliferation is one potential approach to restore ß-cell mass to prevent and/or cure type 1 and type 2 diabetes. While several reports describe the factor(s) that enhance ß-cell replication in animal models or cell lines, promoting effective human ß-cell proliferation continues to be a challenge in the field. In this review, we discuss recent studies reporting successful human ß-cell proliferation including WS6, an IkB kinase and EBP1 inhibitor; harmine and 5-IT, both DYRK1A inhibitors; GNF7156 and GNF4877, GSK-3ß and DYRK1A inhibitors; osteoprotegrin and Denosmab, receptor activator of NF-kB (RANK) inhibitors; and SerpinB1, a protease inhibitor. These studies provide important examples of proteins and pathways that may prove useful for designing therapeutic strategies to counter the different forms of human diabetes.

Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.

The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing with the growing epidemics of obesity and diabetes. NAFLD encompasses a clinicopathologic spectrum of disease ranging from isolated hepatic steatosis to NASH, which is a more aggressive form of fatty liver disease, to cirrhosis and, finally, hepatocellular carcinoma (HCC). The exact mechanism behind the development of HCC in NASH remains unclear; however, it has been established that hepatic steatosis is the important risk factor in the development of HCC. Metformin has recently drawn attention because of its potential antitumor effect. Here, we investigated the effects of metformin on high-fat diet (HFD)-induced liver tumorigenesis, using a mouse model of NASH and liver tumor. Metformin prevented long-term HFD-induced liver tumorigenesis in C57Bl/6 mice. Of note, metformin failed to protect against liver tumorigenesis in mice that had already begun to develop NAFLD. Metformin improved short-term HFD-induced fat accumulation in the liver, associated with the suppression of adipose tissue inflammation. Collectively, these results suggest that metformin may prevent liver tumorigenesis via suppression of liver fat accumulation in the early stage, before the onset of NAFLD, which seems to be associated with a delay in the development of inflammation of the adipose tissue.

Effect of highly lipolyzed goat cheese on HL-60 human leukemia cells: antiproliferative activity and induction of apoptotic DNA damage.

To establish cheese as a dairy product with health benefits, we embarked on examining the multifunctional role of cheeses, especially in the field of cancer prevention. The current study was designed to investigate whether different types of commercial goat cheeses may possess antiproliferative activity, using an HL-60 human promyelocytic leukemia cell line as a cancer cell model. Among 11 cheese extracts tested at 500µg/mL, 6 (Crottin de Chavignol, Pouligny Saint-Pierre, Chabichou du Poitou, Valencay, Kavli, and Sainte-Maure de Touraine) resulted in a significant decrease of cell viability, which is consistent with a decrease in viable cell number. Compared with the half-maximal inhibitory concentration (IC(50)) value of individual cheeses in cellular proliferation assays, the Pouligny Saint-Pierre extract showed strong inhibition. Incubation of cells in the presence of Pouligny Saint-Pierre extract resulted in induction of cellular morphological changes and apoptotic DNA fragmentation as well as expression of the active form of caspase-3 protein. Based on the quantification of the ratio of free fatty acids to triglycerides in different cheese samples, a significant correlation was detected between lipolytic ripeness and IC(50) values for antiproliferative capacity tested in HL-60 cells. Collectively, these results support a potential role of highly lipolyzed goat cheeses in the prevention of leukemic cell proliferation.

Effects of sevoflurane and enflurane on lower esophageal sphincter pressure and gastroesophageal pressure gradient in children.

PURPOSE: The effects of sevoflurane and enflurane on the intraluminal pressure of the lower esophagus (LE), lower esophageal sphincter (LES), and stomach were investigated in paralyzed and mechanically ventilated children under general anesthesia. METHODS: A total of 14 children, ASA physical status class I without risk factors for regurgitation, scheduled for orthopedic surgery were studied. After induction of anesthesia, we inserted a gastrointestinal pressure sensor nasally and monitored the intraluminal pressure of the LE, LES, and stomach under various concentrations of sevoflurane or enflurane with 66% nitrous oxide in oxygen prior to surgical incision. The barrier pressure (BrP), which is the difference between LES pressure and intragastric pressure, was calculated. RESULTS: Sevoflurane at 2.0 and 2.5 minimum alveolar concentration (MAC) decreased LES pressure, and enflurane at 2.0 and 2.5 MAC decreased both LES pressure and BrP in anesthetized children. The intraluminal pressure of the LE and stomach were not altered in either group. CONCLUSION: Sevoflurane and enflurane have an inhibitory effect on LES smooth muscle in anesthetized children. However, since the reduction was relatively low, even at high concentrations, these inhalation anesthetics are unlikely to influence gastroesophageal reflux during anesthesia.

[A case of reflex sympathetic dystrophy following a retinous surgery].

We present a case of a 54-year-old female with post-operative severe continuous ocular pain which occurred 3 months after retinal operation. Her general and mental conditions were good. We diagnosed it reflex sympathetic dystrophy and treated with stellate ganglion blocks (SGB) and continuous cervical epidural blocks. SGB and continuous cervical epidural blocks were effective. With increasing numbers of retinal surgery in recent years, more patients will suffer from postoperative ocular pain. We conclude that SGB or epidural block is useful for the therapy of ocular pain which can not be controlled by drugs and other therapy.

The relaxing effect of ketamine on isolated rabbit lower esophageal sphincter.

We used ketamine to investigate the effects and intracellular mechanisms of several anesthetics on strips of lower esophageal sphincter (LES) from rabbits. Ketamine induced dose-dependent relaxation of LES preparations. It increased the content of 3',5'-cyclic adenosine monophosphate (cAMP) dose-dependently, but decreased that of 3',5'-cyclic guanosine monophosphate (cGMP). Pretreatment with nicotinic acid, an inhibitor of adenylate cyclase, along with atropine to block neurogenic effects, antagonized ketamine-induced relaxation. Pretreatment with N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-89), a selective antagonist for cAMP-dependent protein kinase, similarly antagonized the relaxant effect of ketamine. Cholera toxin and dibutyryl cAMP induced LES relaxation. However, dibutyryl cGMP induced little LES relaxation, and pretreatment with NG-nitro-L-arginine or methylene blue did not alter the relaxant effect. Atropine, propranolol, phentolamine, vasoactive intestinal peptide (VIP) antagonist, and tetrodotoxin did not affect the ketamine-induced relaxation. This response, however, was potentiated in the presence of indomethacin or diphenhydramine. Ketamine-induced relaxation was inhibited in the presence of verapamil. These findings suggest that ketamine induces relaxation of LES, in part, by modulating the activity of adenylate cyclase and in part by inhibiting transmembrane influx of Ca2+.

Effects of various peptides on isolated rabbit lower esophageal sphincter.

Strips of lower esophageal sphincter (LES) from rabbits were tested for their responses to several peptides, and to electrical field stimulation (EFS) under the presence of some peptides. Substance P (SP), motilin, and bombesin induced contraction, and vasoactive intestinal peptide (VIP) induced relaxation. SP- and bombesin-induced contractions were antagonized by SP antagonist. VIP-induced relaxation was antagonized by phentolamine and VIP antagonist. Pretreatment with atropine, phentolamine, and diphenhydramine antagonized the motilin- and bombesin-induced contraction. Pretreatment with tetrodotoxin (TTX) attenuated the motilin- and bombesin-induced contraction, but not the SP-induced contraction and VIP-induced relaxation. EFS induced contraction, which was attenuated by TTX. Calcitonin gene-related peptide and neuropeptide Y had no effect on LES; however, they attenuated EFS-induced contraction. These findings suggest some characteristic peptidergic involvement in rabbit LES smooth muscle.

Effects of an analog of PGF2(alpha) (ONO-1052) on cows with luteinized ovarian cysts following treatment with GnRH analog (fertirelin acetate).

Effects of PGF2(alpha) analog (ONO-1052) on cows with luteinized cysts following treatment with GnRH analog (fertirelin) in inducing estrus and shortening an interval from treatment to conception were investigated in a field trial. Seventy-five cows with follicular cysts diagnosed by rectal palpation were treated intramuscularly (i.m.) with 400 mug fertirelin (an analog of GnRH). Luteinization of follicular cysts were tentatively judged by rectal palpation. Forty-one cows were considered to have luteinized cysts and were either treated i.m. with ONO-1052 (28 cows) or left untreated as controls (13 cows). Thirty-four other cows were considered to have not responded to fertirelin and retreated with 10,000 MU hCG (19 cows) or fertirelin (five cows). This tentative judgment of luteinization of the cysts by rectal palpation after treatment was later confirmed by determining serum progesterone concentration before and 10 to 14 days after treatment. Only in the cows with luteinized cysts which were confirmed by serum progesterone analysis; increased from a pretreatment level below 1.0 ng/ml to a value of 1.0 ng/ml or higher 10 to 14 days after treatment, effects of ONO-1052 combined with fertirelin were investigated. Of the 18 cows with luteinized cysts thus confirmed following fertirelin injection and treated with ONO-1052, 15 (83.3 %) cows came into estrus within 26 +/- 14 (mean +/- SD) days after the first treatment; eight cows within three to five days and four cows within 22 to 28 days, and 14 cows (77.8 %) conceived within 100 days (42 +/- 26 days). On the other hand, the five control cows with luteinized cysts that were not treated with ONO-1052 required significantly longer to exhibit normal estrus (54 +/- 13 days; P<0.05) and to conceive (54 +/- 13 days). These results indicate that ONO-1052 combined with fertirelin may be useful to shorten the interval from treatment to normal estrus and to conception in cows with follicular cysts.